We showed evidence that the CD47 blockade alone had statistically significant but limited efficacy in controlling ES development (Figure 4) which is consistent with previous clinical trial results that CD47 blockade alone is not sufficient to control disease development in solid tumors (30). This evidence concerns the gene CD47 and Ewing sarcoma.